David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy, shared a post on LinkedIn:
“T-Dxd approved in EU as the first tumor-agnostic HER2-directed therapy/ADC for pts with pre-treated, HER2-positive tumours. Very strong efficacy in HER2 3+ NSCLC pts across the DESTINY-Lung01 and Lung03 trials. The main issue will remain reimbursement and access.․․”
1. Title: Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
Authors: Egbert F. Smit, Enriqueta Felip, Dipesh Uprety, Misako Nagasaka, Kazuhiko Nakagawa, Luis Paz-Ares Rodríguez, Jose M. Pacheco, Bob T. Li, David Planchard, Christina Baik, Yasushi Goto, Haruyasu Murakami, Andreas Saltos, Kaline Pereira, Ayumi Taguchi, Yingkai Cheng, Qi Yan, Wenqin Feng, Zenta Tsuchihashi, Pasi A. Jänne
Read the Full Article.
2. Title: Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial
Authors: David Planchard, Hye Ryun Kim, Thatthan Suksombooncharoen, Rubi Li, Diego Cortinovis, Ji-Youn Han, Jens Samol, Yotsawaj Runglodvatana, Kang-Yun Lee, Gee-Chen Chang, Chun-Hui Lee, Dariusz Kowalski, Stephanie P.L. Saw, Yiqing Huang, Gerrina Ruiter, Myung-Ju Ahn, Tsung-Ying Yang, Cheng-Ta Yang, Aumkhae Sookprasert, Erica C. Nakajima, Jose Alfon, Robert McEwen, Yi-Ting Chang, James CH. Yang
Read the Full Article.
You can also read:
